Close
Solutions
Online Inquiry
Global Services

TCR Against Autoimmune Disease

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

As a leading custom service provider that has extensive experience in gene engineering and immunotherapy fields, Creative Biolabs provides high-class TCR generation service for targeting autoimmune disease and other immune-related disorders.

TCR against autoimmune disease

Normally, the task of immune system is protecting our body from a number of diseases and infections, but an autoimmune disorder occurs when the body's immune system attacks and destroys our healthy body tissue by mistake. Autoimmune diseases can be roughly divided into two broad categories: organ-specific autoimmune diseases (e.g. Graves'disease, rheumatoid arthritis (RA), multiple sclerosis (MS)) and systemic autoimmune diseases (e.g. systemic lupus erythematosus (SLE) and Sjogren's disease). It is reported that about 10% of the global population suffer from autoimmune disease, which also affects up to 50 million Americans, according to the American Autoimmune Related Diseases Association (AARDA).To this day, there is still no curative therapy for autoimmune diseases and current treatment focuses on relieving symptoms, which are typically non-specific agents that systemically inhibit inflammatory immune activity. What's more, long-term treatment with the traditional immunosuppressive medicine can alter the ability of the immune system to effectively respond to infectious and neoplastic insults, resulting in severe or even fatal infection and malignancies. It is in urgent need of developing antigen-specific therapeutic approach that can effectively prevent the autoimmune attack and simultaneously leaving the rest of the immune system functioning as normal. The TCR gene therapy strategy of Creative Biolabs is to genetically engineer T cells derived from patients to specifically target autoimmune disease-associated T cells (autoantigens). Theoretically, the T-cell receptor is modified to change the response by the T cell from a disease inducing to a protective response, and still retain the antigen-specificity necessary to target the autoreactive T cells; for example the secretion of cytokines such as IL-10 from engineered T cells can attenuate the response of inflammatory T cells to ease the autoimmune reaction. Thus, our T-cell receptor (TCR) immunotherapy for autoimmune disease is safe and well tolerated in patients, and it can significantly ameliorate symptoms in clinical trials.

Creative Biolabs can perform the TCR affinity optimization aiming to activate the maximum T cell response potential with high specificity to the autoantigen of interest, which can be a great promotion to your research and clinical studies.

Reference:

Taming the TCR: Antigen-Specific Immunotherapeutic Agents for Autoimmune Diseases.

To discuss your demands or to request a proposal, please contact us by .

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.